COVID-19

News

EU starts review of Merck's oral COVID drug molnupiravir

The EMA has started a rolling review of Merck & Co and Ridgeback Biotherapeutics' much-anticipated oral antiviral molnupiravir as a treatment for COVID-19 in adults.

News

FDA advisors mull use of Pfizer/BioNTech COVID-19 jab in kid...

FDA advisors will meet later today discuss the possibility of authorising Pfizer and BioNTech's COVID-19 vaccine Comirnaty in children as young as five years old.

Sales & Marketing

Sustained healthcare systems need sustainable pharma busines...

COVID-19 demonstrated the importance of robust supply chains and the dangers of an over reliance on overseas manufacturing.

News

FDA okays Moderna, J&J COVID jab boosters, plus ‘mix and mat...

The FDA has authorised booster shots with Moderna and Johnson & Johnson’s COVID-19 vaccines, a month after giving the go-ahead to a third-dose of Pfizer/BioNTech’s shot.

News

Delta variant keeps Roche diagnostics sales sky high

High demand for COVID-19 diagnostics driven by the delta variant has led to rocketing sales at Roche's diagnostics division, allowing the company to raise its sales forecast for the year.

News

J&J mulls switch from non-profit status for COVID jab

Johnson & Johnson has been offering its COVID-19 vaccine for sale on a no-profit basis since it became available, but is thinking about a possible switch to a standard commercial model

EU starts review of Merck's oral COVID drug molnupiravir

FDA advisors mull use of Pfizer/BioNTech COVID-19 jab in kid...

Sustained healthcare systems need sustainable pharma busines...

FDA okays Moderna, J&J COVID jab boosters, plus ‘mix and mat...

Delta variant keeps Roche diagnostics sales sky high

J&J mulls switch from non-profit status for COVID jab

NICE guidance calls for quicker diagnosis of PMOS

Discover a new era of healthcare panel engagement: Grounded ...

COVID-19

Editor's Picks